Pharmaceutical products
Oryginalny tytuł ogłoszenia
Germany-Hamburg: Pharmaceutical products
Ocena szansy
Skąd ta ocena?
Szansa
65 / 100
Złożoność
40 / 100
Czynniki ryzyka
The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...
No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...
No procurement documents available
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Przegląd
Strong opportunityKluczowe fakty
- Supplies contract
- 3 lots
- Supply of pharmaceutical products under non-exclusive discount agreements for specified active substances.
- Agreements aim to bridge the period between patent expiry and exclusive discount contracts.
Pokaż pełne podsumowanie
Open house procedure for non-exclusive discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for pharmaceutical products. The notice is a voluntary transparency notice, not a public procurement subject to EU directives. The procedure is open to all qualified pharmaceutical entrepreneurs, with contracts awarded to all who meet the requirements. The contract runs from 1 November 2023 to 31 October 2026, with a possible 6-month extension. Ten lots cover various active substances. No estimated value is provided. Submission of participation and contract documents is electronic via the portal, with continuous accession possible during the contract term.
Ryzyka
The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...
No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...
No procurement documents available
Analiza może być niepełna
Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.
Kluczowe wymagania
Administrative
- Participation is open to pharmaceutical entrepreneurs (as defined in §4 Abs. 18 AMG) who submit a declaration of suitability and reliability.
- Bid submission via electronic portal; documents must be submitted with qualified electronic signature or signed original.
- For timely inclusion of discount pricing in pharmacy software, complete documents must be received by the 3rd of the month prior to the desired start month.
Wymagania mogą być niepełne.
Zamawiający
Lokalizacja
Karlsruhe, DEU
Strona
Działalność
Defence
Części (3)
01
Carbamazepine (RET, N1, N2, N3) - TK, HEK, hkk
Discount agreement for Carbamazepine in specified forms, for participating health insurance funds TK, HEK, and hkk.
Kategoria
Termin
02
Ciclosporin (WKA) - TK, HEK, hkk
Discount agreement for Ciclosporin in specified form, for TK, HEK, hkk.
Kategoria
Termin
03
Levothyroxine sodium (excluding WKA, LSE, TRO, ILO) - TK
Discount agreement for Levothyroxine sodium in specified forms, for TK only.
Kategoria
Termin
Szczegóły zamówienia
- Data publikacji
- 19 Sep 2023
- Języki
- German
Metadane referencyjne
- Podstawa prawna
- 32014L0024
Identyfikatory referencyjne
- ID przetargu
- 566780-2023
Podobne przetargi
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Ocena szansy
Skąd ta ocena?
Szansa
65 / 100
Złożoność
40 / 100
Czynniki ryzyka
The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...
No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...
No procurement documents available
Głęboka analiza portfolio
Wykorzystuje:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications